| 张鲁壮,宋晓洁,崔喜才,祁振国,于 兰.乌司他丁治疗支气管哮喘的临床疗效及血清IL-2, IL-4及T细胞亚群的变化分析[J].,2017,17(20):3893-3896 |
| 乌司他丁治疗支气管哮喘的临床疗效及血清IL-2, IL-4及T细胞亚群的变化分析 |
| Clinical Research of Ulinastatin in Treatment of Bronchial Asthma and Analysis of Changes of Serum IL-2, IL-4 and T Cell Subsets |
| 投稿时间：2017-03-01 修订日期：2017-03-23 |
| DOI：10.13241/j.cnki.pmb.2017.20.021 |
| 中文关键词: 支气管哮喘 乌司他丁 白介素-2 白介素-4 T细胞亚群 |
| 英文关键词: Bronchial asthma Ulinastatin Interleukin-2 Interleukin-4 T cell subsets |
| 基金项目:辽宁省科技厅计划项目(2013226012) |
|
| 摘要点击次数: 340 |
| 全文下载次数: 204 |
| 中文摘要: |
| 摘要 目的：探讨乌司他丁治疗支气管哮喘的临床研究及血清白介素（IL）-2、IL-4、T细胞亚群的变化。方法：选择2014年1月至2016年10月我院接诊的98例支气管哮喘患者，通过随机数表法分为观察组（n=49）和对照组（n=49）。对照组使用常规治疗，包括抗炎、改善通气、纠正酸碱平衡紊乱、雾化吸入糖皮质激素及β2受体激动剂、补充电解质等，观察组联合乌司他丁治疗，均连续治疗7 d。比较两组临床疗效、临床症状消退时间，并于治疗前后采集3 mL空腹静脉血，使用流式细胞仪检测血清IL-2、IL-4、T细胞亚群的变化。结果：治疗后，观察组临床疗效总有效率明显高于对照组（P＜0.05）；观察组呼吸困难、哮鸣音、胸闷、咳嗽症状消退时间明显比对照组短（P＜0.05）；治疗前，两组血清IL-2、IL-4比较差异不明显（P＞0.05），和治疗前比较，两组治疗后血清IL-2、IL-4均得到显著改善（P＜0.05），观察组血清IL-2明显高于对照组，血清IL-4明显比对照组低（P＜0.05）；T细胞亚群中，两组治疗前CD3+、CD4+、CD8+、CD4+/ CD8+比较无显著差异（P＞0.05），治疗后，两组CD3+、CD4+、CD8+、CD4+/ CD8+水平较治疗前均显著改善（P＜0.05），观察组CD3+、CD4+、CD4+/ CD8+ 均比明显对照组高，CD8+明显低于对照组（P＜0.05）。结论：在支气管哮喘患者中应用乌司他丁效果显著，可有效缓解临床症状，改善血清IL-2、IL-4及T细胞亚群的表达，调节机体免疫功能，临床应用价值高。 |
| 英文摘要: |
| ABSTRACT Objective: To study clinical researchof ulinastatin in treatment of bronchial asthma and analysis of the changes of serum interleukin (IL)-2, IL-4 and T cell subsets. Methods: 98 patients of bronchial asthma who received therapy from January 2014 to October 2016 in our hospital were selected. According to random number table, those patients were divided into the observation group (n=49) and the control group (n=49). The control group was treated with routine treatment, including anti inflammation, improve ventilation, correct acid-base balance disorders, inhaled corticosteroids and β2 receptor agonists, electrolytes, etc, while the observation group was combined with ulinastatin treatment. The clinical efficacy and clinical symptom regression time were compared, and collection 3ml fasting venous blood was collected before and after treatment, the changes of serum IL-2, IL-4 and T cell subsets were detected by flow cytometry. Results: After treatment, the total effective rate in the observation group was significantly higher than that of the control group(P＜0.05); the dyspnea, wheeze, chest tightness, cough symptoms subsided time in the observation group was significantly shorter than that of the control group(P＜0.05); before treatment, there was no significant difference in serum IL-2 and IL-4 between the two groups(P＞0.05), compared with before treatment, the serum IL-2 and IL-4 were significantly improved in the two groups after treatment(P＜0.05), the serum IL-2 in the observation group was significantly higher than that of the control group, the serum IL-4 was significantly lower than that of the control group (P<0.05); There was no significant difference in CD3+, CD4+, CD8+ and CD4+/ CD8+ between the two groups (P>0.05), compared with before treatment, the CD3+, CD4+, CD8+ and CD4+/ CD8+were significantly improved in the two groups after treatment (P<0.05), the CD3+, CD4+ and CD4+/ CD8+ in the observation group were significantly higher than those of the control group, and the CD8+ was significantly lower than that of the control group (P<0.05). Conclusion: Ulinastatin is well for bronchial asthma, which can effectively relieve clinical symptoms, to improve the expression of serum IL-2, IL-4 and T cell subsets, regulation of immune function, high clinical value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
